1350887-31-8

Basic information

• Product Name: 4-amino-6-(3-methoxyphenyl)-5-cyano-7-(β-L-xylofuranosyl)pyrrolo[2,3-d]pyrimidine
• Synonyms: 4-amino-6-(3-methoxyphenyl)-5-cyano-7-(β-L-xylofuranosyl)pyrrolo[2,3-d]pyrimidine
• CAS NO: 1350887-31-8
• Molecular Weight: 397.39
• Mol File: 1350887-31-8.mol
• Article Data: 1

Chemical Properties

• CAS DataBase Reference: 4-amino-6-(3-methoxyphenyl)-5-cyano-7-(β-L-xylofuranosyl)pyrrolo[2,3-d]pyrimidine(CAS DataBase Reference)
• NIST Chemistry Reference: 4-amino-6-(3-methoxyphenyl)-5-cyano-7-(β-L-xylofuranosyl)pyrrolo[2,3-d]pyrimidine(1350887-31-8)
• EPA Substance Registry System: 4-amino-6-(3-methoxyphenyl)-5-cyano-7-(β-L-xylofuranosyl)pyrrolo[2,3-d]pyrimidine(1350887-31-8)

Safety Data

• Hazardous Substances Data: 1350887-31-8(Hazardous Substances Data)

Upstream product

• 13039-67-3 (2S,3S,4S)-2-(hydroxymethyl)-5-methoxyoxolane-3,4-diol 
• 670-54-2 ethenetetracarbonitrile 
• 19393-83-0 4-amino-6-bromo-5-cyanopyrrolo[2,3-d]pyrimidine 
• 10365-98-7 3-methoxyphenylboronic acid 
• 609-06-3 L-xylose 
• 98130-58-6 2-amino-5-bromo-1H-pyrrole-3,4-dicarbonitrile 
• 1350887-22-7 4-amino-6-(3-methoxyphenyl)-5-cyano-7-(2,3,5-tri-O-benzoyl-β-L-xylofuranosyl)pyrrolo[2,3-d]pyrimidine 
• 3080-30-6 1-O-acetyl-2,3,5-tri-O-benzoyl-β-L-ribofuranose 

Downstream Products

• 1350887-38-5 4-amino-6-(3-methoxyphenyl)-7-(β-L-xylofuranosyl)pyrrolo[2,3-d]pyrimidine-5-carboxamide 

Relevant articles and documents

Synthesis of 6-(het) ary Xylocydine analogues and evaluating their inhibitory activities of CDK1 and CDK2 in vitro

A series of purine nucleoside analogues bearing an aryl and hetaryl group in position 6 were prepared and their biological activities were assessed by in vitro CDK1/Cyclin B1 and CDK2/Cyclin A2 kinase assay. From the synthesized chemicals, three Xylocydine derivatives 3h, 3i, and 3j exhibited specific inhibitory activities on CDK2/Cyclin A2 with IC50 values of 4.6, 4.8, and 55 μM, respectively. Those three compounds all induced G1/S phase arrest in Human epithelial carcinoma cell line (HeLa), and the results suggested they may inhibit CDK2 activity in vitro. Furthermore, molecular modeling study, their docking into Cyclin Dependant Kinase 2 (CDK2) active site showed high docking scores. Taken together, these data suggest that, those three compounds are good inhibitors of CDK2 for studying this kinase signal transduction pathway in cell system.